View Author
patient survival radiotherapy cancer treatment study factor prognostic trial temozolomide glioblastoma status tumor score eortc analysis hrqol group table scale necrosis oncol baseline outcome performance status research population prognostic factors adjuvant anaplastic promoter phase brain qlq-bn model methylation 1.00 glioma tumour performance resection value 1 ploss 19qloss oligodendroglial signi chemotherapy diagnosis 1·00 surgery grade qlq-bn 20 2 years month quality university analyses review ptk /zk gbm-o van den bene fit anaplastic oligodendroglial tumors fication adjuvant temozolomide hrqol scores prognostic value questionnaire european sample result number toxicity level follow-up inclusion probability feature nomogram erasmus university rotterdam correlation
7 Most Recent Publications
|
Presence of an oligodendroglioma-like component in newly diagnosed glioblastoma identifies a pathogenetically heterogeneous subgroup and lacks prognostic value: central pathology review of the EORTC_26981/NCIC_CE.3 trial
(Article)
Hegi, M.E. Janzer, R.C. Hamou, M.F. Bady, P. Weller, M. Bent, M.J. van den Mason, W.P. Mirimanoff, R.O. Stupp, R. Mokhtari, K. Wesseling, P. Lambiv, W.L. Gorlia, T. Kouwenhoven, M.C.M. Hartmann, C. Deimling, A. von Martinet, D. Besuchet Schmutz, N. Diserens, A.C. |
2012-01-16
|
|
An international validation study of the EORTC brain cancer module (EORTC QLQ-BN20) for assessing health-related quality of life and symptoms in brain cancer patients
(Article)
Taphoorn, M.J. Claassens, L. Aaronson, N.K. Coens, C. Mauer, M. Osoba, D. Stupp, R. Mirimanoff, R.O. Bent, M.J. van den Bottomley, A. |
2010-04-01
|
|
EORTC study 26041-22041: Phase I/II study on concomitant and adjuvant temozolomide (TMZ) and radiotherapy (RT) with PTK787/ZK222584 (PTK/ZK) in newly diagnosed glioblastoma
(Article)
Brandes, A. Stupp, R. Hau, P. Lacombe, D. Gorlia, T. Tosoni, A. Mirimanoff, R.O. Kros, J.M. Bent, M.J. van den |
2010-01-01
|
|
Molecular analysis of anaplastic oligodendroglial tumors in a prospective randomized study: A report from EORTC study 26951
(Article)
Kouwenhoven, M.C.M. Gorlia, T. Vandenbos, F. Grisold, W. Sipos, L. Mirimanoff, R.O. Vecht, C.J. Allgeier, A. Lacombe, D. Bent, M.J. van den Kros, J.M. Ibdaih, A. Brandes, A. Bromberg, J.E.C. Mokhtari, K. Duinen, S.G. van Teepen, J.L.J.M. Wesseling, P. |
2009-12-01
|
|
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial
(Article)
Stupp, R. Hegi, M.E. Hau, P. Brandes, A. Gijtenbeek, J. Marosi, C. Vecht, C.J. Mokhtari, K. Wesseling, P. Villa, S. Eisenhauer, E. Gorlia, T. Mason, W.P. Weller, M. Lacombe, D. Cairncross, J.G. Mirimanoff, R.O. Bent, M.J. van den Taphoorn, M.J. Janzer, R.C. Ludwin, S.K. Allgeier, A. Fisher, B. Belanger, K. |
2009-05-01
|
|
Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3
(Article)
Gorlia, T. Bent, M.J. van den Lacombe, D. Stupp, R. Hegi, M.E. Mirimanoff, R.O. Weller, M. Cairncross, J.G. Eisenhauer, E. Belanger, K. Brandes, A. Allgeier, A. |
2008-01-01
|
|
The prognostic value of health-related quality-of-life data in predicting survival in glioblastoma cancer patients: Results from an international randomised phase III EORTC Brain Tumour and Radiation Oncology Groups, and NCIC Clinical Trials Group study
(Article)
Mauer, M. Stupp, R. Mirimanoff, R.O. Forsyth, P. Bent, M.J. van den Weller, M. Bottomley, A. Taphoorn, M.J. Coens, C. Osoba, D. Marosi, C. Wong, R. Witte, O. de Cairncross, J.G. Efficace, F. |
2007-07-31
|
